BB 1701
Alternative Names: BB-1701Latest Information Update: 22 May 2025
At a glance
- Originator Bliss Biopharmaceutical
- Developer Bliss Biopharmaceutical; Eisai Co Ltd
- Class 2 ring heterocyclic compounds; Antibodies; Antineoplastics; Cyclic ethers; Drug conjugates; Furans; Immunoconjugates; Ketones; Macrocyclic compounds; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HER2 positive breast cancer; Non-small cell lung cancer
- Phase I/II Solid tumours
Most Recent Events
- 13 Sep 2024 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
- 20 Feb 2024 Phase-II clinical trials in HER2-positive-breast-cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Japan (IV), after February 2024 (NCT06188559)
- 20 Feb 2024 Phase-II clinical trials in HER2-positive-breast-cancer (Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (IV) (NCT06188559)